Bladder Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
12278A Clinical Urology Research Screening Protocol
15550B Bladder Cancer Sample Collection
09-152-B CALGB 90601: A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab (IND #7921, NSC #704865) to gemcitabine, cislpatin, and placebo in patients with Advanced transitional cell carcinoma
09-288-B Identification of genetic determinants of response to neoadjuvant cisplatin-based chemotherapy in urothelial cancer
11-0646 S1011: A Phase III Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer
12-1089 RTOG 0926: A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
IRB13-0416 An Integrated Phase II/III, Open Label, Randomized, Parallel and Controlled Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with Non-Muscle Invasive Bladder Carcinoma In Situ Disease (NMIBCis, meaning cis and cis with TA and/or T1) and Who Have Failed BCG Therapy and Refused Cystectomy.
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.